CURIS, INC. Deferred Revenue
CURIS, INC. (CRIS) had Deferred Revenue of $0 as of 2016-12-31, per its 10-K filed 2017-03-09.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2017-03-09
- 2016-12-31: Deferred Revenue, Current $0.00.
- 2015-12-31: Deferred Revenue, Current $0.00.
- 2014-12-31: Deferred Revenue, Current $0.00.
- 2013-12-31: Deferred Revenue, Current $0.00.
| Period end | Deferred Revenue, Current |
|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-09 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-09 |
| 2014-12-31 | $0.00 10-K · filed 2016-02-29 |
| 2013-12-31 | $0.00 10-K · filed 2015-02-24 |
| 2012-12-31 | $0.00 10-K · filed 2014-03-13 |
| 2011-12-31 | $0.00 10-K · filed 2013-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |